Source: USA Today
  • Quipt Home Medical Corp. (QIPT) has signed a contract with Cardinal Health at-Home
  • The agreement stipulates that Quipt will offer to sell, while Cardinal will supply and distribute, disposable medical supplies nationwide
  • Cardinal Health is a distributor of pharmaceuticals, a manufacturer and distributor of medical and laboratory products
  • Quipt Home Medical Corp provides in-home monitoring and disease management services
  • Quipt Home Medical Corp. opened trading at C$6.95

Quipt Home Medical Corp. (QIPT) has signed a contract with Cardinal Health at-Home.

Under the agreement, Quipt will offer to sell, while Cardinal will supply and distribute disposable medical supplies nationwide.

“The execution of this contract with Cardinal Health for the supply of disposable medical supplies is an important milestone for Quipt, and we are thrilled to form this alliance during a period of significant growth,”  stated Greg Crawford, Chairman and CEO of Quipt.

“Cardinal will service our entire operating footprint, consisting of 94 locations across the country aimed at increasing distribution channels while decreasing costs,” he added.

Quipt Home Medical Corp provides in-home monitoring and disease management services including end-to-end respiratory solutions for patients in the United States healthcare market.

It seeks to continue to expand its offerings to include the management of several chronic disease states focusing on patients with heart or pulmonary disease, sleep disorders, reduced mobility, and other chronic health conditions.

Cardinal Health is a U.S.-based distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for health care facilities.

Quipt Home Medical Corp. opened trading at C$6.95.


More From The Market Online

PharmAla Biotech launches educational portal for MDMA

PharmAla Biotech (CSE:MDMA) launches its Prescribers Portal for medical practitioners to learn more about MDMA.

Cancer-fighting pharma stock eyes 2027 regulatory approval

Theralase Technologies (TSXV:TLT), a cancer-fighting pharma stock, expands its team with two clinical research associates.

PharmaDrug-PharmaTher Holdings JV submits clinical, regulatory package

Sairiyo Therapeutics, a PharmaDrug (CSE:PHRX) and PharmaTher Holdings (CSE:PHRM) joint venture, pursues a human clinical study in Australia.